Duchenne muscular dystrophy (DMD) is a rare genetic disease that affects boys almost exclusively and causes progressive weakness.1 With symptom onset typically in early childhood, DMD can be a devastating diagnosis, with few disease-modifying treatment options available.1
At Pfizer, we’re working to rewrite the story of DMD. Inspired by the strength of the DMD community, and with the infrastructure and support network to deliver innovative treatments, our researchers are developing an investigational therapy, now in Phase 2 trial. It is our hope that our scientific resources and knowledge will help give this story a happy ending—new treatment options for patients with DMD.
1National Human Genome Research Institute. Learning about Duchenne muscular dystrophy. http://www.genome.gov/19518854. Updated April 18, 2013. Accessed September 12, 2016.